Skip to main content
NCBI home page
Indian Journal of Clinical Biochemistry logoLink to Indian Journal of Clinical Biochemistry
. 2007 Sep;22(2):17–31. doi: 10.1007/BF02913308

Tumour markers: An overview

T Malati 1,✉
PMCID: PMC3453798  PMID: 23105677

Abstract

Tumor Markers comprise a wide spectrum of biomacromolecules synthesized in excess concentration by a wide variety of neoplastic cells. The markers could be endogenous products of highly active metabolic malignant cells or the products of newly switched on genes, which remained unexprssed in early life or newly acquired antigens at cellular and sub-cellular levels. The appearance of tumor marker and their concentration are related to the genesis and growth of malignant tumors in patients. An ideal tumor marker should be highly sensitive, specific, reliable with high prognostic value, organ specificity and it should correlate with tumor stages. However, none of the tumor markers reported to date has all these characteristics. Inspite of these limitations, many tumor markers have shown excellent clinical relevance in monitoring efficacy of different modes of therapies during entire course of illness in cancer patients. Additionally, determination of markers also helps in early detection of cancer recurrence and in prognostication.

Key words: Tumor Markers, Malignancy, Carcinogenesis, Cancer progression, Prognostic Value

Full Text

The Full Text of this article is available as a PDF (130.7 KB).

References

  • 1.Chu TM. Biochemical markers for human cancer, in Morphological Tumors Markers, general aspects and diagnostic relevance. Seifert G (ed.) Springer Verlag 1987; p: 19–42.
  • 2.Harnden DG. Human Tumor Markers: Biological Basis and Clinical Relevance. J Roy Soc Med. 1985;78:1071–2. [Google Scholar]
  • 3.Virji MA, Mercer DW, Herberman RB. Tumor Markers and their measurements. Pathol Res Pract. 1988;183:95–9. doi: 10.1016/S0344-0338(88)80171-7. [DOI] [PubMed] [Google Scholar]
  • 4.Bates SE, Longo DL. Use of serum tumor markers in cancer diagnosis and management. Semin. Oncol. 1987;14:102–33. [PubMed] [Google Scholar]
  • 5.Paterson AJ, Schlom J, Seares HF. A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG 72) using monoclonal antibody B 72-3. Int J Cancer. 1986;37:659–66. doi: 10.1002/ijc.2910370504. [DOI] [PubMed] [Google Scholar]
  • 6.Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004;6:109–18. doi: 10.1186/bcr777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Fitzgeralk MG, MacDonald DJ, Krainer MG. BRCA1 mutations in Jewish women with early onset breast cancer. N Engl J Med. 1996;334:143–9. doi: 10.1056/NEJM199601183340302. [DOI] [PubMed] [Google Scholar]
  • 8.Villano BC, Brennan S, Brock P. Radioimmunometric assay for monoclonal antibody-defined tumor marker CA 19-9. Clin Hem. 1983;29:549–52. [PubMed] [Google Scholar]
  • 9.Bhattacharya S, Siegel ER, Petersen GM, Chari ST, Suva L, Haun RS. Diagnosis of Pancreatic Cancer Using Serum Proteomic Profiling. Neoplasia. 2004;6:674–86. doi: 10.1593/neo.04262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Paterson AJ, Schlom J, Seares HF. A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG 72) using monoclonal antibody B 72-3. Int J Cancer. 1986;37:659–66. doi: 10.1002/ijc.2910370504. [DOI] [PubMed] [Google Scholar]
  • 11.William MS, Richard G, Kimberly KA, Jerry G, Scott HK, William FS, Philip PT. Comparison of the Sensitivity and Specificity of the CA 19-9 and Carcinoembryonic Antigen assays in detecting cancer of the Pancreas. Gastroenterology. 1986;90:343–9. doi: 10.1016/0016-5085(86)90930-3. [DOI] [PubMed] [Google Scholar]
  • 12.Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary: A clinical and pathological analysis of 71 cases. Cancer. 1976;38:2404–19. doi: 10.1002/1097-0142(197612)38:6<2404::AID-CNCR2820380629>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  • 13.Saraswathi A, Raghunadharao D, Malati T. Cancer antigen CA 125— A current marker for ovarian carcinoma (current diagnostics) Clin Proc NIMS. 1994;9:57–8. [Google Scholar]
  • 14.Saraswathi A, Malati T. Superiority of CA 125 over CA 19-9 and CEA for epithelial ovarian malignancies. Ind J Clin Biochem. 1995;10:23–8. doi: 10.1007/BF02873664. [DOI] [Google Scholar]
  • 15.Fanning J, Walker RLA, Shah NR. Mixed germ cell tumor of the ovary with pure choriocarcinoma metastasis. Obstet Gynecol. 1986;64:5–5. [PubMed] [Google Scholar]
  • 16.Alpert E, Doysdale JW, Isselbacher KJ. Human alphafetoprotein: isolation, characterisation and demonstration of microheterogeneity. J Biol Chem. 1972;247:3792–8. [PubMed] [Google Scholar]
  • 17.Yamashita K, Hitoi A, Tsuchida Y. Sugar chain of alphafetoprotein producing human yolk sac tumor. Cancer Res. 1983;43:4691–5. [PubMed] [Google Scholar]
  • 18.Malati T, Vidya Rani G, Fatima T, Sundari Krishna PT, Ramaswamy S. Maternal serum alphafetoprotein in normal and high-risk pregnancy with a history of repeated abortions. Asian Journal of Clinical Sciences. 1986;6:140–44. [Google Scholar]
  • 19.Fatima T, Malati T, Seeta T. Repeated Anencephaly and XO/XX mosaicism in the mother. Human Genetics. 1982;62:289–289. doi: 10.1007/BF00333541. [DOI] [PubMed] [Google Scholar]
  • 20.Malati T. Alpha fetoprotein in pregnant mothers with reproductive history of Neural tube defects: study of 50 cases. Society of biological chemists India annual conference (abstract) 1984.
  • 21.Malati T, Saraswathi A, Yadagiri B, Kumar A, Dixit VK. Alphafetoprotein in liver disorders. J Int Med Acad Sci. 1995;8:87–90. [Google Scholar]
  • 22.Buamah PK, Gibb I, Bates G. Serum alpha-fetoprotein heterogeneity as a means of differentiation between primary hepatocellular carcinoma and hepatic secondaries. Clin Chem Acta. 1984;139:313–6. doi: 10.1016/0009-8981(84)90277-8. [DOI] [PubMed] [Google Scholar]
  • 23.Talerman A, Haije WG, Baggerman L. Serum Alphafetoprotein (AFP) in patients with germ cell tumors of the gonads and etragonadal sites. Correlation between endodermal sinus (Yolk sac) tumors and raised serum AFP. Cancer. 1980;46:380–85. doi: 10.1002/1097-0142(19800715)46:2<380::AID-CNCR2820460228>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  • 24.Kawai M, Furuhashi Y, Kano T. Alphafetoprotein in malignant germ cell tumors of the ovary. Gynecol Oncol. 1990;39:160–66. doi: 10.1016/0090-8258(90)90425-K. [DOI] [PubMed] [Google Scholar]
  • 25.Malati T, Saraswathi A, Vittal PV, Ananth Reddi P. Elevated serum AFP in a case of endodermal sinus tumor of Nasopharynx. Asean J Clin Sci. 1988;8:33–5. [Google Scholar]
  • 26.Malati T. Tumor Markers in Malignancies: The Role of Alphafetoprotein. Clin Proc NIMS. 1989;4:169–74. [Google Scholar]
  • 27.Wang PY. Alphafetoprotein in non-hepatocellular malignant tumors. Chung-Hua Chun Liu Tsa Chih. 1991;13:61–3. [PubMed] [Google Scholar]
  • 28.Morimoto H, Tanigawa N, Inoue H. Alphafetoprotein-producing renal cell carcinoma. Cancer. 1988;61:84–8. doi: 10.1002/1097-0142(19880101)61:1<84::AID-CNCR2820610114>3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  • 29.Brown JA, Roberts CS. Elevated serum alphafetoprotein levels in primary gall bladder carcinoma without hepatic involvement. Cancer. 1992;70:1838–40. doi: 10.1002/1097-0142(19921001)70:7<1838::AID-CNCR2820700705>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  • 30.Keel BA, Harms RL, Leal JA. Characterisation of human alphafetoprotein charge microheterogeneity during the fetal development. 1990;27:281–7. doi: 10.1002/mrd.1080270402. [DOI] [PubMed] [Google Scholar]
  • 31.Parmelec DC, Evanson MA, Deutsch HF. The presence of fatty acids in human alpha-fetoproteins. J Bio chem. 1978;253:2114–9. [PubMed] [Google Scholar]
  • 32.Smith CJ, Kelleher PC. Alphafetoprotein separation of two molecular variants by affinity chromatography with Concanavalin A agarose Biochem. Biophys Aeta. 1973;317:231–5. doi: 10.1016/0005-2795(73)90218-3. [DOI] [PubMed] [Google Scholar]
  • 33.Breborowicz J. Microheterogeneity of human alphafetoprotein. Tumor Biol. 1988;9:3–14. doi: 10.1159/000217540. [DOI] [PubMed] [Google Scholar]
  • 34.Saraswathi A, Malati T. Clinical Relevance of Alphafetoprotein Microheterogeneity in Alphafetoprotein-Secreting tumors. Cancer Detection and Prevention. 1984;18:447–54. [PubMed] [Google Scholar]
  • 35.Acevedo HF, Tong JY, Hartsock RJ. Human chorionic gonadotropin-beta subunit gene expression in cultured human fetal and cancer cells of different types and origins. Cancer. 1995;76:1467–75. doi: 10.1002/1097-0142(19951015)76:8<1467::AID-CNCR2820760826>3.0.CO;2-A. [DOI] [PubMed] [Google Scholar]
  • 36.Marcillac I, Troalen F, Bidat JM. Free human chorionic gonadotrophin B subunit in gonadal and non-gonadal neoplasm. Cancer Res. 1992;52:3901–7. [PubMed] [Google Scholar]
  • 37.Klee GG, Go VLW. Carcinoembryonic antigen and its role in clinical practice. In: Ghosh BG, editor. Tumor associated antigens and other markers. New York: McGraw-Hill Inc; 1987. pp. 23–43. [Google Scholar]
  • 38.Helfrich G, Klapdor U, Bahlo M. Determination of the tumor markers CA 19-9, CA 125, CA 15-3, CA 50 and CEA in acute and chronic benign diseases in medical/surgical patients. In: Klapdor R., editor. New tumor markers and their monoclonal antibodies— actual relevance for diagnosis and therapy of solid tumors. 4th Symposium on Tumor Markers. Stuttgart New York: George Thieme Verlag; 1987. pp. 287–90. [Google Scholar]
  • 39.Aabo K, Pedersen H, Kjaer M. Carcinoembryonic antigen (CEA) and alkaline phosphatase in progressive colorectal cancer with special reference to patient survival. Eur J Cancer Clin Oncol. 1986;22:211–7. doi: 10.1016/0277-5379(86)90033-7. [DOI] [PubMed] [Google Scholar]
  • 40.Wu JT, Knight JA, Knight DP. ACP Clinical Chemistry Check Sample. Chicago, Ill: American Society of Clinical Pathologists; 1986. CEA in the clinical diagnosis and treatment of colorectal cancer. [Google Scholar]
  • 41.Terry WD, Henkart PA, Coligan JE. Carcinoembryonic antigen: characterization and clinical applications. Transplant Rev. 1974;20:100–129. doi: 10.1111/j.1600-065x.1974.tb00143.x. [DOI] [PubMed] [Google Scholar]
  • 42.Rajani Kumari G, Malati T. Stability of total and free prostate specific antigen in serum samples at different storage conditions. Ind J Clin Biochem. 2004;19:10–13. doi: 10.1007/BF02894250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Malati T, Rajani Kumari G. Racial and ethnic variation of PSA in global population: Age specific reference intervals for serum prostate specific antigen in healthy south Indian males. Ind J Clin Biochem. 2004;19:132–7. doi: 10.1007/BF02872408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Saraswathi A, Malati T. A comparative study of tumor markers of adenocarcinoma prostate. Ind J clin Biochem. 1995;10:29–33. doi: 10.1007/BF02873665. [DOI] [Google Scholar]
  • 45.Malati T, Rajani Kumari G, Murthy PVLN, Rammurthy S, Prayag A, Reddy R et al. The role of free and molecular complexes of PSA, TRUS and DRE and diagnosis and management of BPH and prostate carcinoma. In Proceedings of world congress of pathology and laboratory medicine, published by Medimond, 2003; pp 79–88.
  • 46.Malati T, Rajani Kumari G, Murthy PVLN, Rammurthy S, Ram Reddy Ch, Surya Prakash B. Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate. Ind J Clin Biochem. 2006;21:34–40. doi: 10.1007/BF02913064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Bast RC, Freeney M, Lazarus H, Nadler LM, Coloin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–7. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.O'Brien TJ, Raymond LM, Bannon GA. New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope. Amer J Obstet Gynecol. 1991;165:1857–64. doi: 10.1016/0002-9378(91)90046-t. [DOI] [PubMed] [Google Scholar]
  • 49.Davis HM, Zurawski VR, Bast RC, Klug TL. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Research. 1986;46:6143–8. [PubMed] [Google Scholar]
  • 50.Magnani J, Nilsson B, Brockhous M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V. The Antigen of a Tumor Specific Monoclonal Antibody is a Ganglioside containing sialylated Lacto-N-Fucopentaose II. Federation Proceedings. 1982;41:898–898. [PubMed] [Google Scholar]
  • 51.Saraswathi A, Raghunadha Rao D, Malati T. Cancer Antigen 125 (CA 125)— A current marker for ovarian carcinoma. Current diagnostics. Clin Proc NIMS. 1994;9(2):57–8. [Google Scholar]
  • 52.Saraswathi A, Malati T. Superiority of CA 125 over CA 19-9 and CEA for epithelial ovarian malignancies. Ind J Clin Biochem. 1996;10:23–8. doi: 10.1007/BF02873664. [DOI] [Google Scholar]
  • 53.Malati T, Rajani Kumari G, Yadagiri B. Application of tumor markers in ovarian malignancies. Ind J Clin Biochem. 2001;16:223–4. doi: 10.1007/BF02864868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Bast RC, Xu FJ, Yu YH, Zhang BH, Mills GB. CA 125: The past and the future. The Int J Biol Markers. 1998;13:179–87. doi: 10.1177/172460089801300402. [DOI] [PubMed] [Google Scholar]
  • 55.Rosenthal AN, Jacob IJ. The role of CA 125 in screening for ovarian cancer. The Int J Biol Markers. 1998;13:216–20. doi: 10.1177/172460089801300408. [DOI] [PubMed] [Google Scholar]
  • 56.Beck EP, Moldenhauer A, Merkle E, Kiesewetter F, Jager W, Wildt L, Lang N. CA 125 production and release by ovarian cancer cells. The Int J Biol Markers. 1998;13:200–6. doi: 10.1177/172460089801300405. [DOI] [PubMed] [Google Scholar]
  • 57.Meden H, Fattachi, Meibodi A. CA 125 in benign gynecological conditions. The Int J Biol Markers. 1998;13:231–7. doi: 10.1177/172460089801300411. [DOI] [PubMed] [Google Scholar]
  • 58.Pittaway DE. CA 125 in women with endometriosis. Obstet and Gynecol. Clinics North America. 1989;16:237–52. [PubMed] [Google Scholar]
  • 59.Scharl A, Crombach G, Vierbuchen M, Muesch H, Bolty A. The use of CA 125 as a tumor marker for adenocarcinomas of endocervix, endometrium and fallopian tube. Tumor Diag Therapy. 1989;10:17–20. [Google Scholar]
  • 60.Goecze PM, Szabo DG, Than GN, Csaba IF, Krommer KF. Occurrence of CA 125 and CA 19-9 tumor associated antigens in sera of patients with gynecologic, trophoblastic and colorectal tumors. Gynecol Obstet Invest. 1988;25:268–72. doi: 10.1159/000293797. [DOI] [PubMed] [Google Scholar]
  • 61.Shukla VK, Gurubachan, Sharma D, Dixit VK, Singh U. Diagnostic value of serum CA242, CA19-9, CA 15-3 and CA 125 in patients with carcinoma of the gall bladder. 2006;27:160–5. [PubMed] [Google Scholar]
  • 62.Harmenberg U, Wahren B, Wiechel KL. Tumor markers carbohydrate antigens CA 19-9 and CA 50 and Carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract. Cancer Res. 1988;48:1985–8. [PubMed] [Google Scholar]
  • 63.Magnani J, Steplewski Z, Koprowski H, Ginsburg V. Identification of the Gastrointestinal and Pancreatic Cancer-Associated Antigen Detected by Monoclonal Antibody 19-9 in the Sera of patients as a mucin. Cancer Research. 1983;43:5489–5489. [PubMed] [Google Scholar]
  • 64.Malati T, Rajani Kumari G, Yadagiri B, Shantharam V, Ratnakar KS. Diagnostic utility of tumor markers in identification of unknown primary? Ind J Clin Biochem. 1996;11:77–80. doi: 10.1007/BF02868420. [DOI] [Google Scholar]
  • 65.Duffy MJ, Shering S, Sherry F, McDermott E, O'Higgins N. CA15.3: a prognostic marker in breast cancer. Int J Biol Markers. 2000;1:330–33. doi: 10.1177/172460080001500410. [DOI] [PubMed] [Google Scholar]
  • 66.Nalini R, Delphine W, Silvia CR, Makhija PM, Uthappa S. Usefulness of serum CA15.3 and Histopathological prognostic indices in breast cancer. Ind J Clin Biochem. 2005;20:165–8. doi: 10.1007/BF02893065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Thriveni K, Krishnamoorthy L, Ramaswamy G. Correlation study of carcino embryonic antigen & cancer antigen 15.3 in pretreated female breast cancer patient. Ind J Clin Biochem. 2007;22:57–60. doi: 10.1007/BF02912882. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Ohuchi N, Takahashi K, Matoba N. Comparison of serum assays for TAG 72, CA 19-9, and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol. 1989;19:242–248. [PubMed] [Google Scholar]
  • 69.Villena V, Lopez Encuentra A, Echave Sustaet J. Diagnostic value of CA 72-4, Carcinoembryonic antigen, CA 15-3, and CA 19-9 assay in pleural fluid. Cancer. 1996;78:736–40. doi: 10.1002/(SICI)1097-0142(19960815)78:4<736::AID-CNCR7>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]
  • 70.Holmgren J, Lindholm L, Persson B. Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. Brit Med J. 1984;288:1479–82. doi: 10.1136/bmj.288.6429.1479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Dnistrian AM, Schwartz MK, Greenberg EJ. CA 549 as a marker in breast cancer. Int J Biol Mark. 1991;6:139–43. doi: 10.1177/172460089100600301. [DOI] [PubMed] [Google Scholar]
  • 72.Bethea M, Forman DT. β2 Microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci. 1990;29:163–8. [PubMed] [Google Scholar]
  • 73.Ernerudh J, Olsson T, Berlin G. Cerebrospinal fluid immunoglobulins and β2 microglobulin Lymphoproliferative and other neoplastic diseases of the central nervous system. Arch Neurol. 1987;44:915–20. doi: 10.1001/archneur.1987.00520210017012. [DOI] [PubMed] [Google Scholar]
  • 74.Gupta A, Malati T, Gupta PD. Differential Reduction in the expression of Keratin Polypeptides in human Gastric Carcinomas. Cancer Detection and Prevention. 1997;21:129–34. [PubMed] [Google Scholar]
  • 75.Gupta A, Malati T, Gupta PD. Altered expression of keratin in epithelioid tumors. Current Science. 1992;62:288–93. [Google Scholar]
  • 76.Gupta A, Malati T, Gupta PD. Intracellular proteins as tumor markers. Ind J Clin Biochem. 1992;7:81–8. doi: 10.1007/BF02886659. [DOI] [Google Scholar]
  • 77.Bonfrer JMG, Gaarenstroom KN, Kenter GG. Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. Gynecol Oncol. 1994;55:371–5. doi: 10.1006/gyno.1994.1309. [DOI] [PubMed] [Google Scholar]
  • 78.Pujol JL, Grenier J, Daures JP. Serum fragment of cytokeratine subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res. 1993;53:61–61. [PubMed] [Google Scholar]
  • 79.Weber K, Osborn M, Moll R. tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker. EMBO J. 1984;3:2707–11. doi: 10.1002/j.1460-2075.1984.tb02198.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Kumar S, Costello CB, Glashan RW. The clinical significance of tissue polypeptide antigen (TPA) in the urine of bladder cancer patients. Br J Urol. 1981;53:578–82. doi: 10.1111/j.1464-410x.1981.tb03264.x. [DOI] [PubMed] [Google Scholar]
  • 81.Austin LA, Heath H. Calcitonin: Physiology and pathophysiology. N Engl J Med. 1981;304:269–78. doi: 10.1056/NEJM198101293040505. [DOI] [PubMed] [Google Scholar]
  • 82.Smythe GA, Edwards G, Graham P. Biochemical diagnosis of Pheochromocytoma by simultaneous measurement of urinary excretion of Pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and nor epinephrine. Clin Chem. 1992;38:482–92. [PubMed] [Google Scholar]
  • 83.Horn Y, Beal SL, Walach N. Further evidence for the use of polyamines as biochemical markers for malignant tumors. Cancer Res. 1982;42:3248–51. [PubMed] [Google Scholar]
  • 84.Pogier H, Freis KG, Besse MG, et al. Two site immunoenzymometric assay of the 52 k da cathepsin D cytosols of breast cancer tissues. Clin Chem. 1989;35:81–5. [PubMed] [Google Scholar]
  • 85.Tandon AK, Clark GM, Chamness GC, et al. Cathepsin D and prognosis in breast cancer. N Engl J Med. 1990;322:239–331. doi: 10.1056/NEJM199002013220504. [DOI] [PubMed] [Google Scholar]
  • 86.O'Connor DT, Deftos LJ. Secretion of Chromogranin A by peptide producing endocrine neoplasms. N Engl J Med. 1986;314:1145–51. doi: 10.1056/NEJM198605013141803. [DOI] [PubMed] [Google Scholar]
  • 87.Said JW, Vimadalal S, Nash G. Immunoreactive neuron specific enolase, bombesin and Chromogranin as markers for neuroendocrine lung tumors. Hum Pathol. 1985;1:236–40. doi: 10.1016/S0046-8177(85)80008-3. [DOI] [PubMed] [Google Scholar]
  • 88.Harris AL, Nicholson S, Sainsbury JC. Epidermal growth factor receptors in breast cancer association with early relapse and death, poor response to hormones and interactions with neu. J Steroid Biochem. 1989;34:123–31. doi: 10.1016/0022-4731(89)90072-1. [DOI] [PubMed] [Google Scholar]
  • 89.Elledge RM, Ciocca DR, Langone G. Estrogen receptor, progesterone receptor, and HER 2 neu protein in breast cancers from pregnant patients. Cancer. 1993;71:2499–2506. doi: 10.1002/1097-0142(19930415)71:8<2499::AID-CNCR2820710812>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  • 90.Sombre ER, Hughes A, King WJ. Steroid receptors and breast cancer: current status and new applications for receptor directed diagnosis and therapy. Dev Oncol. 1990;58:155–69. [Google Scholar]
  • 91.Kinoshita Y, Yamada S, Haraguichi K. Determination of vanillylmandilic acid, vanillactic aid, and homovanillic acid in dried urine on filter-paper discs by high performance liquid chromatography with colorimetric electrochemical detection for neuroblastomas screening. Clin Chem. 1988;34:2228–30. [PubMed] [Google Scholar]
  • 92.Jorgensen LGM, Hirsch Fr, Skov BG, et al. Occurrence of neuron specific enolase in tumor tissue and serum in small cell lung cancer. Brit J Cancer. 1991;63:151–3. doi: 10.1038/bjc.1991.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Schroy PC, Brown shimmer S, Kim K. Detection of P21 ras mutations in colorectal adenomas and carcinomas by enzyme linked immunosorbent assay. Cancer. 1995;76:201–9. doi: 10.1002/1097-0142(19950715)76:2<201::AID-CNCR2820760207>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  • 94.Harris CC, Hollstein M. Clinical implications of the P53 tumor suppressor gene. Engl J Med. 1993;329:1312–8. doi: 10.1056/NEJM199310283291807. [DOI] [PubMed] [Google Scholar]
  • 95.Angelopopulou K, Diamandis EP, Sutherland DJA. Prevalence of serum antibodies against the P53tumor suppressor gene protein in various cancers. Int J Can. 1994;58:480–7. doi: 10.1002/ijc.2910580404. [DOI] [PubMed] [Google Scholar]
  • 96.Easton DF, Bishop DT, Ford D. Breast Cancer Linkage Consortium, Breast and Ovarian cancer incidence in BRCA 1 mutation carriers. Am J Hum Genet. 1995;56:104–7. [PMC free article] [PubMed] [Google Scholar]
  • 97.Vogelstein B, Kinzler KW. Has the breast cancer gene been found? Cell. 1994;79:1–3. doi: 10.1016/0092-8674(94)90393-X. [DOI] [PubMed] [Google Scholar]
  • 98.Rio MC, Chambon P. The PS2 gene, mRNA, and protein: a potential marker for human breast cancer. Cancer Cells. 1990;2:269–74. [PubMed] [Google Scholar]
  • 99.Molina R, Fillella X, Torres MD. SCC antigen measured in malignant and nonmalignant disease. Clin Chem. 1990;36:251–4. [PubMed] [Google Scholar]
  • 100.Malati T, Yadagiri B, Murali Mohan Krishna D, Shantaram V, Raghunadharao D, Subba Rao K. Spectrum of Monoclonal Gammapathies in Andhra Pradesh. Ind J Clin Biochem. 2001;16:52–9. doi: 10.1007/BF02867568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Malati T, Yadagiri B, Dinakar I, Sastry BDS, Subba Rao K. Unusual Monoclonal Gammapathies from South India. Trends Clin Biochem Lab Medicine 2003; p. 549–54.
  • 102.Malati T, Jacob R, Singh AK, Subba Rao K. Paraproteinemia —A Review of Clinical, Biochemical and Radiological Aspects. Clin Proc NIMS. 1988;3:120–30. [Google Scholar]
  • 103.Malati T. An overview of Monoclonal G ammapathies. Ind J Clin Biochem. 2001;16:1–8. doi: 10.1007/BF02867561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Yadagiri B. Biochemical studies in Plasma Cell Malignancies with Predominant Osteoclastic Lesions of Bone. Hyderabad: Osmania University; 2004. pp. 1–197. [Google Scholar]
  • 105.Yilmaz G, Yilmaz FM, Senes M, Yucel D. Tumor marker requests in a general teaching Turkish Hospital. Ind J Clin Biochem. 2007;22:52–6. doi: 10.1007/BF02912881. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Indian Journal of Clinical Biochemistry are provided here courtesy of Springer

RESOURCES